Management of Drug-Induced Skin Rash

Assessment and Diagnosis

The American College of Oncology recommends performing a focused physical examination looking specifically for mucosal involvement, skin detachment or epidermal sloughing, and fever >39°C, which may indicate severe hypersensitivity requiring hospitalization 1, 2
Systemic symptoms such as lymphadenopathy, hepatitis, or other organ involvement may indicate DRESS syndrome, according to the Centers for Disease Control and Prevention 3, 1, 2

The American College of Oncology recommends calculating the percentage of body surface area (BSA) involved to guide management, with Grade 1 (<10% BSA) being mild, Grade 2 (10-30% BSA) being moderate, Grade 3 (>30% BSA) being severe, and Grade 4 being life-threatening 1, 2
For Grade 1 reactions, the American College of Oncology recommends applying topical emollients and mild-potency topical corticosteroids, and prescribing oral antihistamines for symptomatic relief of pruritus 1, 2, 3
For Grade 2 reactions, the American College of Oncology recommends applying moderate-to-potent topical corticosteroids, adding oral antihistamines for itch control, and considering dermatology referral and skin biopsy if diagnosis is uncertain 1, 2
For Grade 3 reactions, the American College of Oncology recommends initiating systemic corticosteroids, continuing potent topical corticosteroids and antihistamines, and obtaining dermatology consultation, punch biopsy, and clinical photography 1

The Centers for Disease Control and Prevention recommends obtaining baseline studies to assess for systemic involvement, including complete blood count, comprehensive metabolic panel, and liver enzymes 2, 3
The American College of Internal Medicine warns against using prophylactic corticosteroids or antihistamines when initiating medications known to cause rash, as this strategy has proven ineffective and may actually increase rash incidence 3, 5, 6, 2

The Centers for Disease Control and Prevention notes that antiretrovirals, particularly NNRTIs, can cause rash in the majority of cases, and abacavir requires permanent discontinuation if hypersensitivity occurs 3, 5, 6
The American College of Oncology recommends referring patients to dermatology immediately if there is no response to initial treatment after 2 weeks, diagnostic uncertainty exists, autoimmune skin disease is suspected, or rash progresses despite appropriate management 2, 4

The American College of Oncology notes that improvement typically begins within days of drug discontinuation, new lesions may continue erupting for 2-3 weeks after stopping the medication, and complete resolution usually occurs within 3 months for severe reactions 4